Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro.
Many cancer cell lines and cancers overexpress receptor bound urokinase plasminogen activator on the cell surface. The urokinase plasminogen activator bound to its receptor remains on the cell surface for a prolonged period of time. When urokinase plasminogen activator/urokinase plasminogen activator receptor complex binds plasminogen activator inhibitor (PAI-1), the inhibitor triggers a series of events leading to internalization of the entire complex. This mechanism makes a very attractive target for localization and internalization of PAI-1-based cytotoxic compounds in cancer treatment. We investigated the antitumor activity of PAI-1/A-chain cholera toxin in vitro. Fibrosarcoma-derived HT1080 cells treated with PAI-1 conjugate showed at least 4 times higher cell killing than the control KD normal fibroblast cell line.
Jankun
J
J
Chemistry Department, University of Toledo, Ohio 43606.
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000378:metabolism; D002772:Cholera Toxin / Q000494:pharmacology*; D003102:Colloids; D004355:Drug Stability; D005354:Fibrosarcoma / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology; D006046:Gold; D006131:Growth Inhibitors / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology*; D011956:Receptors, Cell Surface / Q000032:analysis; D055293:Receptors, Urokinase Plasminogen Activator; D012235:Rhodamines; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D003102:Colloids; D006131:Growth Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D012235:Rhodamines; D006046:Gold; D002772:Cholera Toxin